BOT 4.48% 35.0¢ botanix pharmaceuticals ltd

Ann: Ethics Approval for Phase 2 Atopic Dermatitis Study Received, page-66

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 3,544 Posts.
    lightbulb Created with Sketch. 318
    Bernsta I hear these salient issues from you but you are not alone in your ideas. Look at the many listed stocks and you will see similar propositions. If the big boys are buying us, that can only be a good thing. Are they? I reckon not at the moment.

    Step back some time and think of what management has done for we shareholders this year. Many of us were very pissed of at the funding announced for stage 2 trials for acne and dermatitis at the time and there is no doubt whatsoever that this was a closed shop. We got screwed like a Johny Holmes puppet. Those ^&$*holes sold it down to 11cents if I remember BUT was this the case of management being psychic knowing what was in store in late 2018. Imagine getting that now folks !!. So when you curse please consider that they had to entice those low lifes at 11c but YOU can buy it much cheaper now.

    Who the hell here as a shareholder cannot congratulate them NOW for getting Argonaut to stick 11 cents in the air and FULLY FUND stage 2. Fully damn funded. Fully.

    Can I reiterate this again as stage 2 is for ACNE and ATOPIC DERMATITIS. Ah yeah?

    May I please mention that these two are markets worth five billion F#$%% dollars people.

    Cannabinoids look for and activate cannabinoid receptors (CB1 and CB2) and when they get together they tell your body to feel a certain way and do certain things. They also affect and regulate the way other bodily systems function, like your immune, nervous, and gastrointestinal systems.Jun 28, 2018.

    The above details are something that I have found searching around. Think again about what BOT is doing. Bernsta has the angles into what is possible but it all costs a lot of money.

    Being first off the block means a lot of things. BOT is somewhat unique.We do something that is different and we will be noticed. BOT is not a cancer related biotech, it is not a monoclonal antibody type of company that does attract a lot of attention. And costs a fortune.

    I personally believe that Matt and his mates have got a long list of patented inferences that we can go after but how long is a piece of string people.

    Best wishes to all.
    Last edited by beefarmer: 29/12/18
 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
(20min delay)
Last
35.0¢
Change
0.015(4.48%)
Mkt cap ! $707.4M
Open High Low Value Volume
33.5¢ 36.0¢ 33.3¢ $2.583M 7.418M

Buyers (Bids)

No. Vol. Price($)
2 402 37.5¢
 

Sellers (Offers)

Price($) Vol. No.
32.5¢ 810 1
View Market Depth
Last trade - 15.59pm 26/11/2024 (20 minute delay) ?
BOT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.